67 results
S-8
EX-99.4
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
of your Continuous Service for any reason other than Cause, your Disability or your death, except as otherwise provided in Section 7(d) below; provided … Disability, except as otherwise provided in Section 7(d) below;
(d) eighteen months after your death if you die either (i) during your Continuous
S-8
EX-99.3
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death, except as otherwise … of your Continuous Service due to your Disability, except as otherwise provided in Section 7(d) below;
(d) eighteen months after your death if you die
S-8
EX-99.2
ITCI
Intra-Cellular Therapies Inc
25 Jun 24
Registration of securities for employees
4:28pm
) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death, except as otherwise … after the termination of your Continuous Service due to your Disability, except as otherwise provided in Sections 7(d) and 7(e) below;
(d) eighteen
8-K
EX-10.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Departure of Directors or Certain Officers
4:16pm
, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may … Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Other Events
7:37am
with MDD. The baseline MADRS total score was 30.8 for lumateperone 42 mg and 31.5 for placebo.
“MDD is the leading cause of disability in the world, where … represents the primary cause of disability in the world. Symptoms include sadness, hopelessness, helplessness, feelings of guilt, irritability, loss
8-K
EX-99.1
pyt4k
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-10.1
bcq9oke1
5 Jan 22
Financial Statements and Exhibits
4:58pm
PRE 14A
fckymup2
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-10.1
e38wq62 ze27j
28 May 20
Departure of Directors or Certain Officers
4:16pm